Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes

Journal:
JAMA Internal Medicine
Published:
DOI:
10.1001/jamainternmed.2025.7774
Affiliations:
27
Authors:
470
Institutions Authors Share
Novo Nordisk, Denmark
5.000000
0.22
The University of North Carolina at Chapel Hill (UNC), United States of America (USA)
2.000000
0.09
University of Washington (UW), United States of America (USA)
1.000000
0.04
UCL, United Kingdom (UK)
1.000000
0.04
Dalhousie University, Canada
1.000000
0.04
Marienhospital Stuttgart, Germany
1.000000
0.04
Institute for Clinical and Experimental Medicine (IKEM), Czech Republic
1.000000
0.04
Imperial College London (ICL), United Kingdom (UK)
1.000000
0.04
University Hospital Aachen (UKA), RWTH Aachen, Germany
1.000000
0.04
St. Michael's Hospital, Canada
1.000000
0.04
Yale University, United States of America (USA)
1.000000
0.04
Oregon Health and Science University (OHSU), United States of America (USA)
0.500000
0.02
British Heart Foundation (BHF), United Kingdom (UK)
0.500000
0.02
University of Glasgow, United Kingdom (UK)
0.500000
0.02
Steno Diabetes Center Aarhus, Denmark
0.500000
0.02
Aarhus University (AU), Denmark
0.500000
0.02
Michigan Medicine, U-M, United States of America (USA)
0.500000
0.02
Duke-NUS Medical School, Singapore
0.500000
0.02
The University of Texas Southwestern Medical Center (UT Southwestern Medical Center), United States of America (USA)
0.500000
0.02
Parkland Health and Hospital System, United States of America (USA)
0.500000
0.02
University of Erlangen-Nuremberg (FAU), Germany
0.500000
0.02
KfH-Nierenzentrum, Germany
0.500000
0.02
National Heart Centre Singapore (NHCS), Singapore
0.500000
0.02
German Center for Diabetes Research (DZD), Germany
0.333333
0.01
University Hospital Tübingen (UKT), Uni Tübingen, Germany
0.333333
0.01
Institute for Diabetes Research and Metabolic Diseases (IDM), Germany
0.333333
0.01